Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University and the Advanced Research and Invention Agency (ARIA) have agreed a partnership to expand the use of cutting-edge brain and nervous system technologies in patients.
Through joint investment and shared priorities, the collaboration will mean more clinical trials and the development of new treatments at the National Centre for Neurotechnology and Neurorestoration (NCNN) at Newcastle Hospitals.
Established in 2025, the NCNN is the first in the UK dedicated to accelerating the use of pioneering neurotechnologies that interact with the brain and nervous system to help people experiencing significant difficulties with their physical or mental function. This includes conditions such as Parkinson’s disease, epilepsy, motor neurone disease, spinal cord injury, and difficulties with memory, thinking or concentration.
The centre has world-class facilities for clinical trials and the investment will boost the team’s work to research, develop, evaluate and use the latest neurotechnology in patients. This is crucial because advances in technologies, such as *brain-computer interfaces, **neuromodulation and ***neuroprosthetics, are accelerating very quickly and the complexity of moving innovations into routine patient care needs unique expertise in a dedicated environment.
Mr Akbar Hussain, clinical director of the NCNN and consultant neurosurgeon at Newcastle Hospitals, said:
“Neurological conditions are the leading cause of disability worldwide and can be life-changing, causing seizures, loss of movement and communication, issues with mood and difficulties with thinking.
“This funding will support a major boost in our capacity to use the latest neurotechnology to help people who have lost some or all of their normal ability.
“In the last couple of years, we’ve already seen some amazing successes through the use of innovative implant technology, in particular for patients who are living with Parkinson’s disease, paralysis or severe pain.
“It’s very exciting to think about the possibilities that will now be released through the early adoption of even more pioneering technology, to improve the abilities and independence of a wider range of people living with different neurological disorders.”
As the UK’s flagship neurotechnology and neurorestoration centre, the unique NHS-university partnership brings together clinicians, researchers, industry partners and patients in a hospital environment, enabling innovative scientific discovery to be used in direct patient care, reaching the people who need it most.
The funding will grow a specialist workforce of clinical, technical and research staff, and allow the expansion of clinical facilities to meet the needs of neurotechnology innovators.
Dr Luke Bashford, scientific director of the NCNN and researcher at Newcastle University said:
“The National Centre for Neurotechnology and Neurorestoration was created to enable and accelerate the delivery of clinical studies of neurotechnologies, advance research and development, and bridge the gap between scientific discovery and patient benefit. This investment will enable us to scale up this vital work.
“By working with people who have lived experience, innovators and policy makers, we can accelerate the development of safe and effective neurotechnologies, establish new treatments for neurological conditions and strengthen the UK’s position as a global leader in this rapidly growing field.”
The centre also will facilitate the participation of more NHS organisations and research centres in neurotechnology studies, through training and multi-site projects, allowing a greater number of people to gain access to innovative treatments and technologies. In addition, international partnerships will support clinical studies on a larger scale.
Dr Jacques Carolan, programme director at ARIA, said:
“There is an extraordinary amount of innovation in neurotechnology right now. The hard part is not simply inventing a new device — it is working out how to get it to the people who need it most. NCNN gives us a real-world place to do that.
“ARIA’s investment will help build the clinical and regulatory capability needed to translate the most promising neurotechnologies, both within our programmes and across the broader ecosystem, into real-world impact.”
Additional information
* Brain-computer interface – a system (often an implant) that measures brain activity and translates it into commands to control external devices like computers or prosthetic limbs.
**Neuromodulation – technology that alters nerve activity by delivering targeted electrical impulses to specific areas of the brain, spinal cord, or peripheral nerves. Similar to a heart pacemaker, it can intercept, interrupt, or adjust abnormal nerve signals before they cause symptoms like pain or seizures.
***Neuroprosthetics – an artificial device or system that connects directly to the nervous system to replace, restore, or enhance lost motor, sensory, or cognitive function. Microelectrodes, sensors, or non-invasive pads record electrical signals from the brain, spinal cord, or peripheral nerves or electrical pulses are sent directly into them, acting as a bridge to translate thoughts into actions or environmental inputs into neural signals.
About ARIA
- ARIA, an independent body sponsored by the Department for Business, Innovation, Science and Trade, funds breakthrough research and development in underexplored areas of science.
- ARIA funding for NCNN will run for 36 months.
- The funding will support development of the National Centre for Neurotechnology and Neurorestoration as a national hub for neurotechnology research, clinical evaluation and translation.
- ARIA funding and is designed to create lasting public infrastructure capable of supporting future research income, industry collaboration and long-term growth in the UK neurotechnology sector.
About the National Centre for Neurotechnology and Neurorestoration
The NCNN is the UK’s first centre dedicated to new and emerging technologies that interact with the brain and nervous system. Based within Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, the centre aims to accelerate the translation of neurotechnology innovations from research and development through to clinical adoption, improving outcomes for patients with neurological conditions.